Targeting these receptors, through MOR agonists, KOR antagonists like aticaprant, or DOR modulators, offers a promising approach for novel antidepressant therapies, especially in patients with treatment-resistant depression or marked anhedonia (Table 11). The gene discussed is OPRM1; the disease is depressive symptom measurement.